However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...

Fisher & Paykel is well-positioned to benefit from long-term growth prospects in hospital and home respiratory care. Increasing adoption of nasal high flow, or NHF, therapy in the hospital division is ...

The Hostages and Missing Families Forum has celebrated the release of Ofer Kalderon, Yarden Bibas and Keith Siegel, after ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...

Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...

Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call.

Delcath Systems markets Hepzato Kit for the treatment of uveal melanoma with unresectable hepatic metastases. Click here to read my analysis of DCTH stock.

Caitlin Dugdale, MD, MSc, and Kimon Zachary, MD, physicians in the Division of Infectious Diseases at Massachusetts General Hospital (MGH) and assistant professors of Medicine at Harvard Medical ...

Effective patient assessment is essential for improving care quality and ensuring that patients receive the support they need to manage their conditions. Recent research has highlighted various ...

Would you have done anything differently? A friend of mine volunteers at a hospice, and she hears one regret over and over from patients: letting relationships wither. They wish that they had made ...